With 3 Phase 3 retina programs leveraging our 15-year history, Kodiak is at a decisive moment and represents a compelling investment opportunity ABC: antibody biopolymer conjugate; DR: diabetic retinopathy; RVO: retinal vein occlusion; AMD: age-related macular degeneration 4 • High-strength, dual inhibition of IL-6 and VEGF • Safe and potent control of macular edema secondary to inflammation (MESI) KSI-101 Anti-IL-6, VEGF trap bispecific protein For patients with MESI Tarcocimab Anti-VEGF ABC ® biologic KSI-501 Anti-IL-6, VEGF trap bispecific ABC ® biologic For patients with retinal vascular diseases • Strong immediacy • Industry leading durability • BLA filing expected 2026 in 3 indications (wet AMD, DR and RVO) • Improved efficacy beyond anti-VEGF monotherapies • Strong immediacy • Industry leading durability Feb 2026 24-week data from Phase 1b APEX Q4 2026 Topline data from Phase 3 PEAK (MESI) Q2 2027 Topline data from Phase 3 PINNACLE (MESI) Q1 2026 Topline data from Phase 3 GLOW2 (DR) Q3 2026 Topline data from Phase 3 DAYBREAK (wet AMD) BLA filing in 2026 Wet AMD, Diabetic Retinopathy, Retinal Vein Occlusion Q3 2026 Topline data from Phase 3 DAYBREAK (wet AMD) KEY CATALYS TS (expec te d ) Quadrant of core unmet need Quadrant of core unmet need Greenfield market opportunity